Mobile

A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000671-34

A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of the combinations of valsartan/amlodipine 160/10 or 160/5 mg, in patients with essential hypertension not adequately controlled on valsartan 160 mg monotherapy, by testing the hypothesis that either combination of valsartan/amlodipine 160/10 or 160/5 mg produces superior reduction in MSDBP from baseline to 8 weeks compared to valsartan 160 mg alone.

Critère d'inclusion

  • Hypertension

Liens